Hello. This module examines treatment choices for menstrual pain: what the evidence supports, how timing affects relief, and where safety limits matter. Here you will compare nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, with paracetamol (also called acetaminophen) for primary dysmenorrhea—period pain without an identified underlying pelvic condition.
Allow about 35–40 minutes, including the short video and readings. By the end, you should be able to explain why NSAIDs often work better for cramps, what the comparison does and does not establish, and why starting treatment early can matter.
Why the medicines differ
At the start of a period, the uterine lining releases prostaglandins. These chemical messengers stimulate the uterus to contract. Strong contractions can temporarily reduce blood flow within the uterine muscle, contributing to cramping pain. In primary dysmenorrhea, this process causes pain without an identified underlying pelvic condition.
NSAIDs reduce the production of prostaglandins by inhibiting enzymes called cyclooxygenases, or COX enzymes. That puts them close to a major driver of primary menstrual cramps. Paracetamol can relieve pain, but it does not suppress uterine prostaglandin production to the same extent at usual doses. This distinction helps explain why two familiar pain medicines may perform differently for this particular kind of pain.
Should Periods Hurt? - Causes, Treatments, Medication
Watch the selected passages from “Should Periods Hurt? - Causes, Treatments, Medication” by Dr Simi Adedeji for a visual explanation of the cramping mechanism and an introduction to treatment timing.
Watch the cramping mechanism for the connection between prostaglandins, contractions, reduced blood flow, and pain. Later, watch starting early and delayed treatment. Focus on the contrast between treating the first signs of cramps and waiting until pain is intense; the exact dosing schedule still depends on the medicine’s label and your circumstances.
What the comparison shows
The most useful evidence is not simply that ibuprofen can help. It is whether NSAIDs relieve primary menstrual pain more often than no active medicine, and whether they outperform paracetamol. A Cochrane review assembled randomized trials to address both comparisons.
Nonsteroidal anti-inflammatory drugs for dysmenorrhoea | Cochrane
Read Cochrane’s evidence summary to see how the treatment comparison was studied and how confidently its results can be interpreted.
In “Background” and “Study characteristics,” read from mechanism and trials. Then, below “Read the full abstract,” use the subsections “NSAIDs versus placebo” and “NSAIDs versus paracetamol.” Read placebo results and direct comparison. Finish with evidence limitations, immediately before and within “Authors’ conclusions.” Keep the placebo and paracetamol comparisons separate as you read.
The review estimated that, where 18 out of 100 people taking a placebo achieved moderate or excellent pain relief, roughly 45–53 out of 100 taking an NSAID would do so. Those numbers illustrate benefit against placebo; they are not a numerical comparison with paracetamol.
In the direct NSAID-versus-paracetamol comparison, NSAIDs appeared more effective. That conclusion rests on only three trials, however, and the review rated the evidence for most comparisons as low quality, largely because study methods were poorly reported. The sensible conclusion is directional: NSAIDs are generally the better-supported choice for primary cramps, but the precise size of their advantage over paracetamol is uncertain. “Less effective on average” also does not mean paracetamol never helps.
Benefit must be considered alongside harms. In the review’s placebo comparison, estimated reports of side effects were 10 out of 100 with placebo and 11–14 out of 100 with NSAIDs. Indigestion, headache, and drowsiness were among those reported. The direct comparison provided too little adverse-effect information to conclude that NSAIDs and paracetamol are equally safe. Nor was there strong evidence that one individual NSAID is consistently best for everyone.
Why starting time matters
Prostaglandin activity is highest around the beginning of bleeding. Because NSAIDs inhibit prostaglandin production, starting before cramps become intense may work better than waiting until pain has built up. This is a rationale for early, appropriately spaced treatment during the painful days, not a reason to take extra doses.
Clinical guidance makes the timing distinction more concrete:
Read the “NSAIDS” subsection of the American Family Physician article for its treatment-timing recommendation and the practical reasons relief sometimes falls short.
Under “NSAIDS,” begin with the paragraph opening “Nonsteroidal anti-inflammatory drugs.” Read timing guidance. Then move to the next paragraph, opening “Despite the known effectiveness,” and read practical limits. The doses later in the first paragraph are clinical examples, not instructions to copy for over-the-counter use.
For a predictable period, the article recommends beginning an NSAID one to two days before bleeding starts and taking it at regular intervals through the first two to three days of bleeding. If the start is unpredictable, beginning at the first mild cramps or when bleeding begins is a more workable approach than guessing a date far in advance. In either case, follow the appropriate product label or a clinician’s instructions for intervals and duration.
The article’s recommendation fits the biology, but do not mistake timing for a guarantee. Even appropriately used NSAIDs do not relieve everyone’s pain. A later-than-ideal start is one possible reason for disappointing relief, not proof that timing is the only problem. Likewise, increasing a dose beyond its label is not a sound way to compensate for starting late.
Putting the evidence into a treatment decision
For typical primary menstrual cramps, an NSAID is often preferred over paracetamol because it targets prostaglandin production and has better evidence for pain relief. Paracetamol remains a possible pain-relief option when an NSAID is unsuitable or not tolerated, though it may provide less relief for cramps. Neither medicine should be treated as universally safe.
This lesson compares effectiveness and timing, not individual dosing. NSAID suitability can change with factors such as a history of stomach ulcers or bleeding, kidney problems, certain medicine interactions, or possible pregnancy. Paracetamol also has important dose limits and can appear in more than one product. The next lesson will address how to check a specific over-the-counter plan against an age-appropriate local label and personal risk factors.
Finally, a response to pain medicine does not establish its cause. Pain that is worsening, persistently disruptive, or unlike your usual pattern deserves clinical assessment rather than repeated attempts to adjust treatment timing alone.
Key takeaways
NSAIDs, including ibuprofen, inhibit COX enzymes and reduce the prostaglandins that drive many primary menstrual cramps. They outperform placebo and appear to relieve cramps better than paracetamol, although the direct comparison is based on limited, low-quality evidence. Starting an NSAID early—before expected bleeding when cycles are predictable, or at the first signs of cramps when they are not—fits its mechanism and clinical guidance. Effective timing never overrides label limits or individual safety considerations.
Next, you will use those limits to assess whether a proposed over-the-counter pain-relief plan is safe.